scholarly journals Olfactory disfunction and diabetic complications in type 2 diabetic patients: a pilot study

Endocrine ◽  
2021 ◽  
Author(s):  
Francesco Mozzanica ◽  
Anna Ferrulli ◽  
Stela Vujosevic ◽  
Alessandro Montuori ◽  
Arianna Cardella ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Diabetic Complications ◽  
Control Group ◽  
Subjective Perception ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Olfactory Abilities ◽  
Type 2 Diabetic

Abstract Purpose Scarce information on the prevalence and characteristics of olfactory disfunction (OD) in type 2 diabetic (T2D) patients are available. The aims of this study were (1) to assess the olfactory function in T2D patients and to compare it with a control group of individuals without T2D, and (2) to evaluate the differences in OD within T2D patients according to the presence of diabetic complications. Methods A group of 39 T2D patients and a control group of 39 healthy individuals were enrolled. Each subject underwent an evaluation of the olfactory performance using the Sniffing Olfactory Screening Test (SOST) and completed a questionnaire assessing the subjective perception of olfaction. According to the presence of diabetic complications, the group of T2D patients was divided into two subgroups. Non-parametric tests and regression analysis were used for statistical analysis. Results No differences in the subjective perception of olfaction were demonstrated among T2D patients (with and without complications) and controls. A significant difference for the SOST score was demonstrated among the different groups. In particular, OD was more frequent in T2D patients than in controls. In addition, OD was far more frequent in T2D patients with complications. Regression analysis did not demonstrate any significant association between OD and clinical/demographic characteristics of T2D patients. Conclusion T2D patients were more frequently affected by OD. The subgroup analysis suggested a possible relationship between OD and diabetic complications since patients with T2D diabetic complications demonstrated lower olfactory abilities than controls subjects and T2D patients without diabetic complications.

scholarly journals Effect of Different HIIT Protocols on the Glycemic Control and Lipids Profile in Men with type 2 diabetes: A Randomize Control Trial

2020 ◽  
Author(s):  
Hessam Golshan ◽  
Mohammadreza Esmaelzadeh Toloee ◽  
Hamid Abbasi ◽  
Nasim Namiranian
Keyword(s):  
Type 2 Diabetes ◽  
High Volume ◽  
Control Group ◽  
P Value ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Low Volume ◽  
Type 2 Diabetic

Objective: : High intensity interval training (HIITs) can induce weight control, lowering blood pressure and beneficial effects on cardiovascular health in type 2 diabetic patients. The effect of different volumes of these exercises is unclear in type 2 diabetic patients. The aim of this study was to compare the effect of low volume and high volume of short-term intensive training on glycemic indexes of men with type 2 diabetes. Materials and Methods: Thirty type 2 diabetes male patients who were referred to Yazd diabetes research center (30 - 46 years old) were selected and randomly divided into 3 groups of low and high volume HIITs groups and control group. The intensity of the exercises in low volume was up to 110% and in high volume up to 80% of the maximum heart rate. The two training groups performed exercises 3 days of week for 8 weeks. Glycemic factors and lipids profile were measured before and after the last training session. Data were analyzed by covariance and paired T-test. Results: Low volume HIIT exercises significantly decreased the glucose ( P -value: 0.01), HbA1c ( P -value: 0.01), insulin ( P -value: 0.005), insulin resistance ( P -value: 0.001), and triglyceride ( P -value: 0.04). Low volume HIIT in the insulin resistance had a significant difference with the control group ( P -value: 0.04). High density lipoprotein in high volume group had a significant difference with the control group ( P -value: 0.021). Conclusion: Low-volume HIIT exercises can be a nonpharmacological approach to improving glycemic factors in type 2 diabetic patients.

scholarly journals Impairment of Erythrocyte Deformability Observed in Type 2 Diabetic Patients with Clustering Diabetic Complications

2020 ◽  
pp. 27-37
Author(s):  
Takeshi Arita ◽  
Taku Yokoyama ◽  
Shohei Moriyama ◽  
Mitsuhiro Fukata ◽  
Kei Irie ◽  
...  
Keyword(s):  
Diabetic Complications ◽  
Statistical Significance ◽  
Microvascular Dysfunction ◽  
Erythrocyte Deformability ◽  
Control Group ◽  
Diabetic Patients ◽  
Qtc Interval ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Aims: Hemorheologic and microvascular dysfunction are interdependent in type 2 diabetic patients. However, exact mechanisms explaining this interaction remains unclear. This study aimed to investigate the impairment of erythrocyte deformability under concurrent recording of electrocardiogram (ECG), since heart-rate-corrected QT interval (QTc interval) prolongation reflects autonomic and microvascular dysfunction in diabetic patients. Methodology: The erythrocyte deformability was investigated on the day of digital ECG recording in diabetic (n = 215) and control (n = 88) groups of outpatients using specific filtration technique. Significant contributors to the erythrocyte deformability were analyzed by multivariate analysis. Results: Difference of mean erythrocyte deformability in the diabetic vs. control group did not reach the statistical significance, but the difference was significant in comparison of diabetic smokers vs. non-smokers and of diabetic patients with vs. without diabetic complications. Impaired diabetic erythrocyte deformability was dependent mostly on the glycated hemoglobin (HbA1c), and negative correlation between QTc interval and the deformability was marginal. Conclusions: Erythrocyte deformability was not necessarily impaired in diabetic patients under the intensive antidiabetic medication. However, this deformability was impaired in diabetic smokers and diabetic patients with clustering of complications. Future studies are required for hemorheologic and microvascular interaction leading to the impaired diabetic microcirculation.

scholarly journals Serum Selenium Status in Patients with Type 2 Diabetes and Control Group

2016 ◽  
Vol 9 (5) ◽  
pp. 234
Author(s):  
Zahra Heidari ◽  
Zahra Sepehri ◽  
Aleme Doostdar
Keyword(s):  
Type 2 Diabetes ◽  
Serum Level ◽  
Control Group ◽  
Diabetic Patients ◽  
Diabetes Incidence ◽  
Serum Selenium ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
The Mean

<p>In addition to known risk factors, the role of different micronutrients such as selenium in diabetes incidence has been proposed. Some previous studies have shown an association of selenium deficiency and type 2 diabetes mellitus, while other studies have not confirmed such a relationship. The aim of this study was to evaluate serum level of selenium in patients with Type 2 diabetes compared with the control group. This cross-sectional study was carried out on patients with type 2 diabetes in Zahedan, southeastern Iran. One hundred newly diagnosed type 2 diabetic patients were evaluated for serum selenium level. One hundred subjects from the general population who had normal fasting blood sugar levels were selected as the control group. The control group subjects were matched in pairs with each of patients on the basis of sex, age (± one year), and body mass index (±1). Serum level of selenium was determined by spectrometry method. Results were compared using t-test. The mean serum level of selenium in patients was 94.47±18.07 µg/L whereas in control group was 142.79±23.67 µg/L. The mean serum level of selenium was significantly different between the two groups (P&lt;0.001). Serum levels of selenium in diabetic patients with significant difference statistically were lower than the control group. In order to evaluate serum level of selenium in patients with diabetes, studies with larger sample size are required. Likewise, prospective studies along with selenium supplementation and investigating its effect on incidence of diabetes are accordingly needed.</p>

Investigating ADAMTS7 and ADAMTS12 levels in prediabetic and Type 2 diabetic patients

2021 ◽  
Author(s):  
Mercan Taştemur ◽  
Selvihan Beysel ◽  
Sema Hepşen ◽  
Sanem Öztekin ◽  
Erman Çakal ◽  
...  
Keyword(s):  
Inflammatory Markers ◽  
Diabetic Patients ◽  
Control Groups ◽  
Type 2 Diabetic Patients ◽  
Human Enzyme ◽  
Significant Difference ◽  
And Control ◽  
Type 2 Diabetic

Background: This study aims to investigate the role of ADAMTS7 and ADAMTS12 on atherosclerosis and inflammation in prediabetic and diabetic patients. Patients & methods: Serum ADAMTS7 and ADAMTS12 levels were compared with the atherosclerotic and inflammatory markers in diabetic (n = 65, female 30.9%, mean age = 53 years), prediabetic (n = 55, female 36.6%, mean age = 49 years) and control groups (n = 55, females 32.5%, mean age = 49 years). Serum ADAMTS levels were determined by a human enzyme-liked immunoassay. Results: In terms of ADAMTS7, there was no significant difference between diabetic, prediabetic and control groups (50.93, 44.34, 59.07, respectively; p > 0.05). ADAMTS12 is lower in diabetics (p < 0.05), whereas it is similar in prediabetics and controls (14.53, 20.76, 25.05, respectively; p > 0.05). ADAMTS7 and ADAMTS12 levels did not differ in diabetic nephropathy, retinopathy and neuropathy (p > 0.05). Conclusion: While ADAMTS12 was significantly lower in diabetics and prediabetics, ADAMTS7 and ADAMTS12 were not related to diabetic complications (nephropathy, retinopathy and neuropathy).

scholarly journals Islet cell and glutamic acid decarboxylase-65 autoantibodies in young diabetic patients attending in a General Hospital in Dhaka City

2020 ◽  
Vol 46 (2) ◽  
pp. 104-108
Author(s):  
Ashesh Kumar Chowdhury ◽  
Shahjalalur Rahman Sahi ◽  
Mohammad Moniruzzaman ◽  
Mansura Khan
Keyword(s):  
Beta Cell ◽  
Diabetic Control ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Gad 65 ◽  
Glutamic Acid Decarboxylase 65 ◽  
Type 2 Diabetic

Background: Immune mediated destruction of pancreatic beta cell in type-I diabetes is well established but its’ role in young type-2 diabetic patients is still not conclusive. These young diabetic patients pass through several stages where they do not need insulin but found to have serum autoantibody against islets cell and even become dependent on insulin for survival in course of time. This study aims to find the presence of islets cell auto-antibodies (ICA) and autoantibody to glutamic acid decarboxylase-65 (GAD-65) in non-insulin requiring young diabetic patients of Bangladesh. Objective: To evaluate the presence of ICA and GAD-65 between the non-insulin requiring young type-2 diabetic patients and compare with the non-diabetic control group. Method: This case control study was carried out at the Department of Immunology, BIRDEM General Hospital, Dhaka for a period of one year from July 2013, A total of 120 non-insulin requiring (≥12 months) young type-2 diabetic patients and 60 age, sex matched non-diabetic were enrolled as control subjects following inclusion and exclusion criteria. ICA and GAD-65 tests were performed by enzyme linked immune-sorbent assay (ELISA) method by using kits from DRG Inc. International, USA. Results: In this study statistically significant difference found between non insulin requiring young diabetic patients and non diabetic control in respect of positive ICA result (p=0.015). The moderately strong negative association was found between different age of onset of diabetes mellitus and value of ICA level (r=-0.45). Only 20-24 years age group showed statistically significant difference between patient and control (p=0.013). Statistically significant difference was not found in GAD-65 values of non insulin requiring young diabetic patients and non diabetic controls (p=0.441). Conclusion: This study revealed that there is significant difference present in respect of ICA among non-insulin requiring young diabetic patients and non-diabetic controls. Therefore, autoimmune pathogenesis of beta cell killing by producing ICA against islets cell take place in young type-2 diabetic patients. Bangladesh Med Res Counc Bull 2020; 46(2): 104-108

scholarly journals Comparison of Lipid Profile in Type-2 Obese Diabetics and Obese Non-diabetic Individuals. A hospital Based Study from Western Nepal

2013 ◽  
Vol 10 (3) ◽  
pp. 44-47 ◽  
Author(s):  
Naval Kishor Yadav ◽  
C Thanpari ◽  
MK Shrewastwa ◽  
RK Mittal
Keyword(s):  
Lipid Profile ◽  
Venous Blood ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Serum Triglycerides ◽  
Control Subjects ◽  
Significant Difference ◽  
The Mean ◽  
Type 2 Diabetic

Background Type-2 diabetes mellitus is an independent risk factor for coronary artery disease and risk of coronary disease is three to four fold increased in patients with diabetes compared with non-diabetic population and 60-80% 0f type-2 diabetics are obese. Methods This study was conducted in Nepalgunj Teaching Hospital, Kohalpur, Banke, Nepal, between 1st March, 2011 and 28th February, 2012. A total of 150 samples were taken to assess the lipid profile in type-2 diabetic patients associated with obesity and 25 obese controls for their lipid profile. Venous blood samples were taken from all the subjects in the morning after fasting overnight. Exclusion criteria included pregnancy, chronic infectious disease, heart failure; renal failure and drug allergy were confirmed from the subject’s personal physician report and a detailed history. The data was analyzed using Excel 2003, R 2.8.0 Statistical Package for the Social Sciences (SPSS) for Windows Version 16.0 (SPSS Inc; Chicago, IL, USA) and the EPI Info 3.5.1 Windows Version. Results The mean ± SD age of diabetic patients with obesity was 53.76 ± 6.23 while the mean ± SD age of control was 49.61 ± 4.8. Out of 150 patients 105 (70%) were males and 45 (30%) were females. Among control subjects 16 (64%) were males and 9 (36%) were females. Obese type-2 diabetic patients when compared to obese control subjects showed statistically significant increase in the levels of serum total cholesterol (p ? 0.001), serum triglycerides (p ? 0.001), serum LDL-cholesterol (p ? 0.001) while serum HDL-cholesterol levels did not show statistically significant difference in the two group (p ? 0.05). Conclusion This study showed obese diabetic individuals have dyslipidemia and more prone to develop cardiovascular diseases. Kathmandu University Medical Journal | VOL.10 | NO. 3 | ISSUE 39 | JUL- SEP 2012 | Page 44-47 DOI: http://dx.doi.org/10.3126/kumj.v10i3.8017

scholarly journals Quality of Life in Type 2 Diabetic Patients

2014 ◽  
Vol 31 (3) ◽  
pp. 193-200 ◽  
Author(s):  
Ana Spasić ◽  
Radmila Veličković Radovanović ◽  
Aleksandra Catić Đorđević ◽  
Nikola Stefanović ◽  
Tatjana Cvetković
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Short Form ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Cross Sectional ◽  
Significant Difference ◽  
Type 2 Diabetic

Summary The presence of diabetes mellitus leads to a decrease in life quality in all domains. The aim of our study was to evaluate the quality of life (QOL) in diabetic patients and the factors affecting it in type 2 diabetic mellitus patients. We conducted a cross-sectional study that included 86 patients with type 2 diabetes mellitus, in the territory of the City of Niš. Health-related QOL of patients was measured using the short form survey (SF-36) that produces an 8-scale health profile. The average duration of diabetes was 12.76±8.08 years. The best QOL in all areas was observed in patients diagnosed with diabetes less than 10 years ago p<0.05) and younger than 65 years. Male respondents perceived a better QOL compared to women, especially in the vitality and pain domains. The patients with comorbidity (93.64%) had lower QOL score in all domains. There was no significant difference in the QOL of patients with diabetes compared to the level of education. High QOL represents an ultimate goal and an important outcome of all medical interventions in diabetic patients. Factors related to lower QOL included: older age, female gender, and existence of comorbidities. Uncontrolled diabetic patients had a lower QOL than controlled diabetics.

Prevalence of diabetic complications in fibrocalculous pancreatic diabetic patients and type 2 diabetic patients

2004 ◽  
Vol 18 (5) ◽  
pp. 264-270 ◽  
Author(s):  
Karuna Kanta Barman ◽  
Mahesh Padmanabhan ◽  
Gopal Premalatha ◽  
Raj Deepa ◽  
Mohan Rema ◽  
...  
Keyword(s):  
Diabetic Complications ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Serum IL-17, IL-23, and TGF-βLevels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Azam Roohi ◽  
Mina Tabrizi ◽  
Farzaneh Abbasi ◽  
Asal Ataie-Jafari ◽  
Behrouz Nikbin ◽  
...  
Keyword(s):  
Serum Levels ◽  
Diabetic Patients ◽  
Low Grade ◽  
Healthy Controls ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factorβ(TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-βlevels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-βwere measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-βwas significantly lower in type 1 diabetic patients (P<0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-βlevels were lower in type 1 diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document